Your browser doesn't support javascript.
A Comparison of Gam-Covid-Vac (Sputnik V) Vaccine Immunogenicity in Hemodialysis Patients and Non-Renal Subjects
Kidney International Reports ; 8(3 Supplement):S455-S456, 2023.
Article in English | EMBASE | ID: covidwho-2275731
ABSTRACT

Introduction:

We report results on immunogenicity of the recombinant adenovirus (rAd) 26 and rAd5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by Gamaleya National Research Centre, Russia) in patients, receiving maintenance hemodialysis (HD). We aimed to compare the dynamics of humoral and cellular immunity after 2 doses of Gam-COVID-Vac in patients receiving HD and individuals with normal kidney function. Method(s) We recruited 23 patients treated with maintenance HD and 28 volunteers with normal kidney function (control group). All participates were adult, had been vaccinated twice with Gam-COVID-Vac vaccine and had no prior history of confirmed COVID-19. In all participants, the levels of anti-SARS-CoV-2-specific IgG were quantified at 1 month and 6 months from the second vaccine shot using ELISA. Specific T-cell responses (CD4+ and CD8+ cytotoxic T-lymphocytes) were evaluated using the TIGRA-test (Generium, Russia) at the same timepoints. [Formula presented]

Results:

Participant's characteristics and tolerability data are summarized in Table 1. Patients receiving HD were older and had more comorbidities compared with the control group. The seropositivity rate declined in both groups over time and was 100% vs 68% in non-renal controls and 91% vs 50% in HD group at months 1 and 6, respectively. In both groups, IgG levels decreased from month 1 to 6, however, antibodies did not vanish more rapidly in the HD group (analysis of variance p = 0.709 for the "time x group" interaction, age-adjusted model) - Figure 1. [Formula presented] IgG levels correlated inversely with age of HD patients (rho= -0.42 [95% CI -0.64;-0.13], p=0.0047), whereas no correlation was observed in control group. Initially, the T-test result was positive in 79% non-renal and 73% HD subjects. At the end of the study, 48% non-renal and 64% HD participants showed T-cell positivity. T-spot responses to SARS-CoV-2 structural peptides S did not differ in the control group and in patients receiving HD at month 1 (p = 0.75) and 6 (p = 0.6) after vaccination. However, T-spot counts dropped over time in non-renal controls, but not in HD subjects (p=0.008 and p=0.18, respectively) - Figure 2. Over the course of the study, there were 2 confirmed cases of COVID-19 reinfection in control group, and 1 case in HD group. Conclusion(s) Patients receiving hemodialysis maintain significant long-term humoral response after vaccination with Gam-COVID-Vac vaccine, which is comparable to that in subjects with normal kidney function. Cellular response turned up to be more sustained over time in HD group. [Formula presented] No conflict of interestCopyright © 2023
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Kidney International Reports Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Kidney International Reports Year: 2023 Document Type: Article